{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029065","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.116784+00:00","generated_at":"2026-05-26T01:05:40.785940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cardiff Oncology reports Q4 cash $91.7M; 64% ORR for onvansertib plus SOC in RAS-mut mCRC","bullets":["64% objective response rate (ORR) for 30mg onvansertib + SOC vs 33% control in first-line RAS-mut mCRC trial (CRDF-004).","Raised $40M oversubscribed registered direct offering; cash runway extended into Q1 2027.","Full-year 2024 net cash used $37.7M; operating expenses $49.3M, up $3.4M YoY.","USPTO issued patent for onvansertib + bev in bev-naïve KRAS-mut mCRC, expiring no earlier than 2043.","Additional CRDF-004 clinical data expected in 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029065","json":"https://secwatch.observer/filing/0000950170-25-029065.json","markdown":"https://secwatch.observer/filing/0000950170-25-029065.md","text":"https://secwatch.observer/filing/0000950170-25-029065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/0000950170-25-029065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017025029065/crdf-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:05:40.785940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}